Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company that specializes in developing novel immunotherapies to treat various infectious diseases and cancers. The company was founded in 2011 and is headquartered in New York City, with additional facilities in Vienna, Austria.
The core focus of Hookipa Pharma is on the development of proprietary technologies that aim to stimulate the body's immune system to fight diseases. They utilize a unique viral vector platform called VaxWave®, which is designed to deliver specific antigens directly to the target cells, triggering a potent immune response. This platform has the potential to generate robust and long-lasting immune responses against a range of diseases.
The company's pipeline includes candidates targeting diseases such as human papillomavirus (HPV), cytomegalovirus (CMV), and various forms of cancer. Hookipa's lead product candidate, HB-101, is being developed as a potential treatment for patients with advanced HPV16-positive cancers. The company is also actively exploring the application of their platform in other therapeutic areas, including infectious diseases and autoimmune disorders.
Hookipa Pharma went public on April 18, 2019, with an initial public offering (IPO) on the NASDAQ Global Market under the ticker symbol "HOOK." The IPO allowed the company to raise funds to support its ongoing research and development efforts and advance its pipeline of immunotherapies.
Since going public, Hookipa has continued to advance its clinical programs and expand its pipeline. The company has entered into collaborations with various partners to leverage its technology platform and explore potential combination therapies. These collaborations aim to enhance the efficacy and scope of Hookipa's immunotherapies and maximize their potential impact on patients.
As a biopharmaceutical company focused on immunotherapies, Hookipa Pharma is at the forefront of innovative approaches to combat infectious diseases and cancers. Through its proprietary VaxWave® platform, the company aims to revolutionize the field of immunotherapy and provide new treatment options for patients in need. With ongoing clinical development and research, Hookipa is dedicated to advancing the understanding and application of immunotherapies to improve patient outcomes and quality of life.